VBI Vaccines — World Vaccine Congress 2017
24 slides from VBI Vaccines's conference presentation, Apr 11, 2017
Slide 1: Harnessing Foreign Viral CMV Antigens to Restimulate Anti-Tumor Immunity
gill os > VBI VACCINES Zay iit lm HARNESSING FOREIGN VIRAL CMV ANTIGENS TO RESTIMULATE ANTI-TUMOR IMMUNITY WORLD VACCINE CONGRESS NASDAQ: VBIV TSX: VBV APRIL 11, 2017
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forword-looking information under applicable Canadian securities legislation (collective
Slide 3: The Immuno-Oncology Renaissance Depends on Appropriate Antigen Selection
The Immuno-Oncology Renaissance Depends on an Ability to Activate Anti-Tumor Immunity via Appropriate Antigen Selection Historic Context of Cancer Vaccines Nature Review Artice'en "Neoantecns: ‘Schumacher & Schrieber, Science, April 2015 + Historically: weakly immunogenic “self” tumor associated ant
Slide 4: Evidence for CMV as a Target Antigen in GBM
aSsssss—_______ Evidence for CMV as a Target Antigen in GBM Multiple Independent Labs Have Confirmed the Presence of CMV in GBM Tumor Samples, but not in Adjacent Healthy Tissue * Cobbs CS (2002) Immunohistochemical (IHC) staining with CMV pp65 antibody confirmed expression in 22/22 GBM tumor sample
Slide 5: Evidence for CMV as a Target Antigen in GBM
aSsssss—_______ Evidence for CMV as a Target Antigen in GBM C: negative control Ab E: pp65 stained GBM sample aD Lucas KG(2011) Primary GBM Tumors Present Antigens Recognized by CMV Specific T-cells A cewv pp 6s effectors ad wis 100/Patient 4 25 Patient 5 | ‘| 5 Targets —W- DC-pp65 ANA 2 DC-survivin
Slide 6: Clinical Evidence Supporting CMV as a Cancer Immunotherapeutic Target
a ______ Clinical Evidence Supporting CMV as a Cancer Immunotherapeutic Target Body of Evidence Suggests a CMV Vaccine That Can Stimulate DCs & Restimulate CMV-specific T-cells Has Potential for Clinical Efficacy * Prins RM (2008) Autologous, GBM tumor lysate-loaded DC vaccine Single immunization in
Slide 7: CMV is Highly Expressed in Multiple Solid Tumors
a ______ CMV is Highly Expressed in Multiple Solid Tumors Breast Medullo-blastoma * Taher C(2013) J Clin Virol Baryawno N(2011) J Clin 54, 240; Invest 121, 4043-4055; * Harkins LE (2010) * Libard S(2014) PLoS ONE Herpesviridae 1, 8 9, €108861; Neuroblastoma Meningioma * Wolmer-Solberg N (2013) * Lib
Slide 8: Leveraging CMV Viral Antigens Provides Opportunity to Attack Tumors
Leveraging CMV Viral Antigens Provides Opportunity to Attack Tumors NOT Predicted to be Susceptible to PD-1/CTLA-4 Alone PD-1/CTLA-4 Success Rate is Dependent on Availability of Suitable Antigens Peguty chia >90% CMV Positive! 23.45: Success with Great potential for VBI-1901 PD-1 1) WoimerSoerg Net
Slide 9: VBI-1901: Construct Design & Rationale
VBI-1901: Construct Design & Rationale Zmyy Ne NASDAQ: VBIV | TSX: VBV. 3
Slide 10: Enveloped Virus-Like Particles (eVLPs) Enable Potent Delivery of Vaccine Antigens
Enveloped Virus-Like Particles (eVLPs) Enable Potent Delivery of Vaccine Antigens in an Effective Viral Mimic Flexible, Customized Antigen Delivery in a Biologically Relevant Construct MLV Gag Creates Structure — internal Targets Promote Cellular Immunity Glycoprotein Target Antigen pid Membrane fro
Slide 11: VBI-1901: A Rationally Designed Therapeutic CMV Vaccine
SSS === VBI-1901: A Rationally Designed Therapeutic CMV Vaccine Highly Potent Antigens Delivered a Next-generation VLP ‘Anti-gB Antibodies #1 Antibody target for CMV (to stimulate ADCC) CMV gB 8 binding is known to potentiate tumor growth! ‘Anthgb Ch4+J-helper cells #1 CD4+ T-helper cell target 5 +
Slide 12: VBI-1901: Addresses Multiple Unmet Medical Needs
aSsssss—_______ VBI - 1901: Addresses Multiple Unmet Medical Needs Glioblastoma (GBM) + GBMis the most aggressive form of brain cancer + Median overall survival is 14.6 months, only 30% will live two-years? + Standard of care is Temodar + surgery + ~90% of patients will experience recurrent GBM? + M
Slide 13: VBI-1901: Proof of Concept Data
ally, VBI-1901: Proof of Concept Data Yy Zo NASDAQ: VBIV | TSX: VBV. B
Slide 14: VBI-1901: Restimulates CD4+ and CD8+ T-cell Responses Ex Vivo
a ______ VBI-1901: Restimulates CD4+ and CD8+ T-cell Responses in CMV-positive Human Subjects Ex Vivo Restimulation of CD4+ & CD8+ T-cells in Ex Vivo Human Samples * Fresh PBMCs stimulated with VBI-1901 vs recombinant antigens CD4*IFN-y* CD8tIFN-;* + eVLPs rapidly restimulate both Frequency of Respo
Slide 15: VBI-1901 eVLPs Stimulate CCL3 when Expressing CMV gB and pp65 Antigens
VBI-1901 eVLPs Stimulate CCL3 when Expressing CMV gB and pp65 Antigens Stimulation of CCL3 biomarker correlated with improved clinical outcome after CMV pp65 DC vaccination of patients with GBM (Mitchell et al, 2015) VBI-1901 stimulation of CCL3 S CCL3 Secretion (pgiml) NASDAQ: VBIV | TSX: VBV.
Slide 16: VBI-1901 Induction of CCL3 in ex vivo PBMCs from CMV-Positive Subjects
VBI-1901 Induction of CCL3 in ex vivo PBMCs from CMV- Positive Healthy Subjects and Patients with Solid Tumors Stimulation of CCL3 biomarker correlated with improved clinical outcome after CMV pp65 DC vaccination of patients with GBM (Mitchell et al, 2015) CCL3 Secretion - oe E 10 oc 15: = 25 > oa c
Slide 17: Balanced Cellular & Humoral Immunity in Mice Immunized with VBI-1901
a ______ Balanced Cellular & Humoral Immunity in Mice Immunized with VBI-1901 pp65-specific Th1 cells gB-specific CTLs gB-specific antibody response 1.0 = 108 Antibody Titer (6MT} CD3*CD4*IFNy* (%) CD3*CD8*perforin* (%) ° ES ee ‘G4 $ NASDAQ: VBIV | TSX: VBV. v
Slide 18: GM-CSF Improves the Potency of gB/pp65 eVLPs After Intradermal Vaccination of Rabbits
aSsssss—_______ GM-CSF Improves the Potency of gB/pp65 eVLPs After Intradermal Vaccination of Rabbits 3 Interpolated Endpoint Titer (OD=0.1) Ss ie N a x we x? “ CS N & aie 3
Slide 19: VBI-1901: Potential for an Off-the-Shelf Dendritic Cell Vaccine
VBI-1901: Potential for an “Off-the-Shelf” Dendritic Cell Vaccine gB/pp65 eVLPs Recruit (CCL3) and Activate (IL-8) Dendritic Cells CCL3 LB _& 2500: i = = = 2000: 2 EH © i “+ CCL3: gps evLPs 1500 “= oBipp65 eVLPs g = COL Huron sn abumin Bg = Human serum albumin § 2 8 soo! 3 3 °. °. os) 100190200 32 4
Slide 20: VBI-1901: Scalable Manufacturing with Exceptional Purity
a ______ VBI-1901: Scalable Manufacturing with Exceptional Purity SDS-PAGE Analysis of VBI-1901 eVLP Purity During Downstream Processing NASDAQ: VBIV | TSX: VBV. Samples (3ug total protein, reducing/denaturing conditions) Lane 1: Ladder (Precision Plus Protein Standard) Lane 2: Harvest Lane 3: Clari
Slide 21: Biodistribution Study: Intradermal Injection of VBI-1901
Biodistribution Study: Intradermal Injection of VBI-1901 eVLP particles do not accumulate in major organs voi Ne NASDAQ: VBIV | TSX: VBV.
Slide 22: Analysis of eVLP Biodistribution
Analysis of eVLP Biodistribution 2 ono 2 aoe i = vaum aro Sse = amen arn < parte) = oo = ar 4c0e : ra) H B20 £ aa g a 2 va 3 0 =I 3 0 —————p OF 4 6 6 tom 4 46 10 20 22 4 02 4 6 6 10 12 1 0 0 2 Time (hn) Time (hn) eVLP particles persist at the injection site but not within the brain thr 24hr 0° 2 one
Slide 23: VBI-1901: Targeting Solid Tumors Through Innovative Use of Foreign Viral Antigens
SSS === VBI-1901: Targeting Solid Tumors Through Innovative Use of Foreign Viral Antigens Next Generation Cancer Vaccine Leverages Natural Anti-Viral Immunity + Tumor-associated viral CMV antigens represent a unique “off-the-shelf” vaccination opportunity relevant to multiple solid tumors + CMVis hi
Slide 24: itll
itll WZ SS :2 svbiz eS Za VBI Vaccines, Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 Adam Buckley abuckley@vbivaccines.com NASDAQ: VBIV | TSX: VBV.